Implications for employers: This research suggests that those who are treated effectively with GLP-1 medications for obesity will need to remain on these for the long term
Ready to make an appointment
Several mechanisms are thought to contribute, and these should be understood as hypotheses based on the drug's pharmacology and observations from related incretin-based therapies: Reduced caloric intake: Retatrutide significantly suppresses appetite, often leading to a substantial reduction in food consumption
doi:10.3390/jcm12010145 3.Perkovic V, Tuttle KR, Rossing P, et al
Best for: menopause-stage readers who want GLP-1 and HRT in one place
Williams adds that new studies are uncovering benefits involving other chronic diseases, such as heart disease, Type 1 diabetes and polycystic ovary syndrome (PCOS)